Tags : Rivipansel

Pfizer Reports Results of Rivipansel in P-III RESET Study for

Tuba Khan August 5, 2019

Shots: The P-III RESET study involves assessing of Rivipansel (IV) vs PBO in 345 patients in a ratio (1:1) with SCD who were hospitalized for a VOC and required treatment […]readmore

Tags : Rivipansel

Pfizer Reports Results of Rivipansel in P-III RESET Study for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Rivipansel

﻿Pfizer Reports Results of Rivipansel in P-III RESET Study for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Pfizer Reports Results of Rivipansel in P-III RESET Study for